
TAVI IN MEDICOR-SLOVENIA

Marko Noc on behalf of Medicor **TAVI** team


Medicor symposium December 16, 2022 Portoroz (SLO)



CTA post ULM PCI /TAVI (B. Cveticanin, MD)

No conflict of interest

THE STORY OF STRUCTURAL PROGRAM IN MEDICOR...



When I did my first aortic balloon valvuloplasty, my mentor Franck Litvack mentioned Alain Cribier...

Cribier A, Savin T, Saoudi N, Rocha P, Berland J, Letac B. Percutaneous transluminal valvuloplasty of acquiered aortic stenosis in elderly patients: an alternative to valve replacement? Lancet 1986;1(8472):63-7.

...AND BECAME A FRIEND WITH SAIBAL...

October 27, 2006



Saibal arrived with Starflex device...and start teaching us PFO closure


DEC. I	000
PFO closure	330
ASD closure	45
VSD closure	1
LAA closure	33
Ablation/HOCMP	12
Paravalvular leak	1
TAVI	389
TAVI	389

FIRST TAVI IN MEDICOR (December 16, 2016)

Lady, 78 years
Normal coronaries
ES II 1.51/STS 2.27



General anesthesia/Intubation/TEE BAV 18 mm, Evolut R29, no post BAV



Echo before TAVI

- Mean gradient 56
- EF 70%



Echo at discharge:

- Mean gradient 13
- Mild AR
- EF 70%



Echo after 5 years:

- Mean gradient 14
- No AR
- EF 60%



Doing very well also after 6 years

Operators: Oscar Mendiz, Saibal Kar, Marko Noc

MC MEDICOR "TAVI TEAM"

- Interventional cardiologists (A. Pleskovič, M. Noc)
- Echocardiographists (N. Černič, D. Petrovič, R. Stopar)
- TAVI CTA radiologist (B. Cvetičanin)
- Cardiac anesthesiology team (N. Danojevič, V. Tomič)
- Cardiac surgery (M. Đorđevič, M. Špan, S. Sušak)
- Scrub nurse/X-ray (A. Čerpnjak, T. Godeša, R. Brečko)
- Cardiologists/Nurses in the department
- Registry: M. Rojko

Prof. dr. Metka Zorc - The "Alpha and Omega" of Medicor

Oscar Mendiz, Buenos Aires



Flavio Ribichini, Verona






ALWAYS READY TO HELP US...







MC Medicor-unpublished

TAVI PATIENTS IN MEDICOR (n=374)

Age, years 80<u>+</u>6 (60-95)

Men, n (%) 183 (49%)

LVEF, % 57<u>+</u>11 (22-80)

PAP, mm Hg (if increased) 37±12 (17-70)

Post PCI/CABG 119 (32%)

Logistic Euroscore 17.2 \pm 13.2 (1.7-80.4)

Euroscore II 4.1 <u>+</u>4.2 (0.7-50.1)

STS score 2.9<u>+</u>2.1 (0.4-16.0)

Max gradient, mm Hg 75<u>+</u>17 (33-128)

Mean gradient, mm Hg 47<u>+</u>12 (18-84)

AVA, cm2 0.8±0.2 (0.4-1.2)

Bicuspid valve 14 (3.7%)

Surgical bioprothesis 14 (3.7%)

MC Medicor-unpublished

PROCEDURAL FEATURES

Conscious sedation 332 (89%)

Femoral-percutaneous 371 (99.2%)

Subclavian cut down 2 (0.5%)

Femoral cut down 1 (0.3%)

Predilatation 167 (45%)

Valve implantation 371 (99.5%)

Evolut /Sapien 3 327 (88%)/45 (12%)

Postdilatation 69 (18%)

Mitroflow or Trifecta 8/14 (57.1%)

Coronary protection/stenting 8/14 (57.1%)

ViV BVF 4/14 (28.6%)

ViV BVR 4/14 (28.6%)

MC Medicor-unpublished

TAVI IN MEDICOR (n=374)

Results

Post TAVI mean gradient 10±4 (3-24)

AR moderate/severe 32 (8.7%)/2 (0.5%)

New permanent pace maker 55 (15%)

TIA/CVI 2 (0.5%)/3 (0.8%)


30-day mortality 6 (1.6%)

Major complications

LV perforation/tamponade	2 (0.5%)
RV perforation (PM wire)	3 (0.8%)
Annular/aortic rupture/tamponade	2 (0.5%)
Aortic dissection type A	1 (0.3%)
Infrarenal aortic dissection	1 (0.3%)
Illiac artery rupture	1 (0.3%)
Retroperitoneal hematoma	1 (0.3%)
Acute LM obstruction	1 (0.3%)
Anaphylactic shock (Protamin)	1 (0.3%)

Emergency interventions

Cardiac surgery	3 (0.8%)
Vascular surgery	3 (0.8%)
Pericardiocenthesis	3 (2.2%)
ULM stenting	1 (0.3%)



MC Medicorunpublished

SAVR/TAVI 30-DAY MORTALITY IN MC MEDICOR

Pre TAVI era (2011-2016)	SAVR/Mortality	TAVI/Mortality	All/Mortality
N (%)	435 (2.3%)	-	435 (2.3%)
Mean age, years	71	-	
Mean Log Euroscore	9.2		

TAVI era (2017-2022)	SAVR/Mortality	TAVI/Mortality	All/Mortality
N (%) Age, years Mean Log Euroscore	568 (2.1%) 71 7.5	374 (1.6%) 80 <u>+</u> 6 17.2	942 (1.9%)

- TAVI increased number of treated patients due to by inclusion of older/sicker patients who were previously rejected for SAVR
 - This did not increase 30-day mortality at Medicor

PERMENENT PACE MAKER IMPLANTATION AFTER TAVI IN MEDICOR

Year	TAVR (n)	Alerady on PM	New PPI		
2016-17 2018 2019 2020	24 47 71	0 (0%) 2 (8.3%) 3 (6.4%) 5 (7.0%)	4 (36.4%) 8 (36.4%) 8 (18.2%) 10 (15.2%)	-	Cusp overlap for Evolut December 11, 201
2021 2022 All	112 109 374	9 (8.0%) 8 (7.3%) 27 (7.2%)	17 (16.5%) 9 (8.9%) 56 (14.9%)	—	Target 1-2 mm instead of 3-5 on non-coronary cus in 2022

Increased experience and optimal utilization of cusp overlap decreased PPI<10% despite 88% use of Evolut


PERCUTANEOUS FEMORAL CLOSURE

CTA analysis for puncture site


Routine contralateral 0.018 wire



Flouro-guided puncture





Sheathless Evolut valve implantatioin



Submited to CRT 2023


PLAN AND REALITY IN INTERVENTIONAL CARDIOLOGY...






A 81-year old man with significant ULM-LAD stenosis and aortic stenosis presenting in 2017...

1. PCI ULM-LAD




2. TAVI (Evolut R 29)



ASA and Clopidogrel according to PCI (6months)

AFTER 4 MONTHS...

- Partial recurrence of symptoms (still on ASA/Clopidogrel)
- Mean echo gradient increased from 12 to 23 mm Hg




Clopidogrel maintaned, ASA replaced with cumadine (INR 2-3), PPI

WHAT HAPPENED?

- Symptomes gradually resolved
- Mean echo gradient down to 9 mm after 3 months and to 12 mm after 7 months
- Cumadine replaced with ASA at 7 months-again on ASA/Clopidogrel
- After 7 months, dispnoe and exertional angina, gradient 20 mm Hg....







TREATMENT PLAN:

Resolve HALT/RELM before PCI to avoid thrombus dislodgment/embolization by guide manipulation

- ASA replaced with cumadine clopidogrel keept (again)
- Mean echo gradient again decreased to 10 mm Hg after 3 months
- CT confirmed HALT/RELM resolution
- Progress of LM-LAD ISR



CORONARY ANGIOGRAPHY AND PCI ...



DES 3.5x14
Postdilatation
3.5 NC (24atm)



- ASA, Clopidogrel and cumadine for 1 month with PPI protection
- Clopidogrel and cumadine lifelong with PPI protection

HOW IS HE DOING NOW?